This was achieved by a reduction in VLDL-TG production rate ( PR ) compared with placebo ( -32 % , p = 0.008 ) or ATV ( -20 % , p = 0.03 ) as well as a reciprocal increase in VLDL-TG FCR ( +42 % , p < 0.05 ) compared with placebo .